| Features: |
| Irinotecan is a chemotherapy drug widely used to treat several solid tumors. It is a semisynthetic camptothecin derivative and functions primarily as a topoisomerase I inhibitor. -Active metabolite: SN-38 (much more potent than irinotecan itself) Common Regimens Regimen Components FOLFIRI Folinic acid + 5-FU + Irinotecan FOLFIRINOX 5-FU + Leucovorin + Irinotecan + Oxaliplatin XELIRI / CAPIRI Capecitabine + Irinotecan Potential strategies to sensitize tumors to irinotecan: Strategy Rationale GSH depletion Reduces detox of SN-38 PRDX/TXNRD stress Lowers redox buffering Glycolysis inhibition Limits repair energy PEMF / AgNPs ↑ ROS, ↑ drug uptake Timing selenium Avoid boosting antioxidant defenses during therapyReport of combining CPT-11 and SeNPs to increase NRF2 in normal cells(chemoprotective) and decrease NRF2 in cancer cells(chemosentization). |
| 4734- | Se, | CPT-11, | Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles |
| - | in-vitro, | CRC, | HCT8 | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:380 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid